Japan Prices Sovaldi Well Below U.S.
This article was originally published in PharmAsia News
Japan has granted a reimbursement price to Gilead's hepatitis C drug Sovaldi as the first all-oral therapy for the disease in the country, with each pill priced well below U.S. levels but still set to cost the national healthcare insurance system upwards of $500.
You may also be interested in...
Corporate consolidation and specialization were major threads running through the 2010s in Japan. Reimbursement pricing issues continued to dominate the policy sphere while new forms of therapy benefited from positive regulatory reforms.
BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.
BeiGene’s license agreement with Leap Therapeutics covers Asia, except for Japan, along with Australia and New Zealand. Apollomics obtains rights in China and beyond to GlycoMimetics’ e-selectin antagonists.